Subdural hematomas during CML therapy with imatinib mesylate

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Imatinib mesylate is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML).
• Subdural hematomas are a rare but serious complication that can occur in patients with hematological malignancies.
• The potential association between imatinib mesylate and subdural hematomas requires further investigation.

Purpose of the Study:

• To investigate the incidence and characteristics of subdural hematomas in CML patients treated with imatinib mesylate.
• To identify potential risk factors associated with the development of subdural hematomas in this patient population.
• To evaluate the outcomes and management strategies for CML patients experiencing subdural hematomas during imatinib therapy.

Main Methods:

• Retrospective analysis of 121 CML patients treated with imatinib mesylate.
• Detailed review of clinical data, including disease stage, blood counts, and treatment regimens.
• Documentation of subdural hematoma occurrence, management, and patient outcomes.

Main Results:

• Seven out of 121 CML patients (5.8%) developed subdural hematomas while on imatinib mesylate.
• All affected patients had advanced CML and were initially treated with a high dose of imatinib (600 mg/day).
• Subdural hematomas occurred irrespective of platelet count or white blood cell count at diagnosis, with three patients having neither.
• Four patients required surgical intervention, one patient died from the hematoma, and three died from progressive CML.

Conclusions:

• Subdural hematomas are a potential complication of imatinib mesylate treatment in CML patients, even with normal peripheral blood counts.
• Mildly symptomatic patients receiving imatinib should be evaluated for subdural hematomas.
• Imatinib therapy can be cautiously resumed in patients who survive subdural hematomas, with some achieving significant responses.